Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of intravenous OMN6 in healthy adults
NL-OMON51720Phase 1Active, not recruiting
- Sponsor
- Omnix Medical
- Start
- Mar 2022
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in bacterial disease and Acinetobacter baumannii infection comparing OMN6 with Matching placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2022; status: active, not recruiting.
02
Drugs
OMN-6
03
Conditions
bacterial diseaseAcinetobacter baumannii infection
Beyond the preview
Go deeper on NL-OMON51720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51720.